The Tobacco/Nicotine Industrial Complex: The Impact of Revenue on Tobacco Harm Reduction Policies

A complex web of economic forces heavily influenced by divergent state tax policies across the United States sustains the traditional cigarette industry’s dominance despite the rise of reduced-risk nicotine products. The U.S. tobacco/nicotine industrial complex currently generates approximately $100 billion in revenue, making it a significant economic force despite long-term declines in smoking. The industry supports jobs in farming, manufacturing, retail, and related sectors but faces headwinds from falling adult smoking rates. Taxes on traditional tobacco products generate substantial government revenue that is often used to fund public health initiatives; however, the shift in consumer preferences for untaxed or lower-taxed nicotine alternatives is reshaping fiscal dynamics. While public health objectives aim to curb smoking, fiscal realities and incentives for state and federal revenues combine with the impact of taxation on consumer behavior to discourage a shift away from combustible cigarettes.

The cost to produce a pack of cigarettes in the United States primarily refers to direct manufacturing expenses, such as raw materials (i.e., tobacco, paper, filters), labor, and processing. Based on available data from major manufacturers, this cost is low compared to the retail price, which includes significant taxes as well as indirect marketing and distribution expenses. In 2012, the manufacturing cost for one pack of 20 Marlboro Gold cigarettes was reported as $0.26  (excluding marketing, administrative overheads, taxes, and profits). According to 2011 data, tobacco farming costs in North Carolina (the largest source of tobacco in the United States) were around $1.34 per pound, with the 0.06 pounds of tobacco per pack contributing roughly $0.08 cents to the raw material cost. However, full manufacturing adds processing and assembly expenses. Adjusting for inflation would bring this closer to $0.35-$0.40 today, though actual costs could vary by brand, scale, and region due to labor wages, regulatory compliance, and other factors. As cigarette sales decline, the impact on the supply chain is significant. For example, reduced demand for cigarettes has led to fewer farms, smaller harvests, and crop diversification. The number of U.S. tobacco farms plummeted from 93,530 in 1997 to about 3,000 in 2022, with leaf harvests dropping from 1.74 billion pounds to 431.6 million pounds.

States derive significant revenues from the sales of tobacco and nicotine products through two primary mechanisms: consumer taxes and tobacco industry payments resulting from the 1998 Master Settlement Agreement (MSA).

State tax revenues include excise taxes on cigarettes (typically per pack), other tobacco products including cigars, smokeless tobacco, and pipe tobacco and, increasingly, electronic nicotine delivery systems (ENDS) like e-cigarettes and vaping products. These taxes generate significant revenue that could be directed toward public health initiatives. The average state cigarette tax is $1.93 per pack, ranging from $0.17 in Missouri to $5.35 in New York.

The intentions of these taxes are threefold:

• To provide funding to offset the costs associated with smoking.
• To prevent future smokers from taking up the habit.
• To reduce consumption, particularly among youth and low-income groups.

However, the outcomes are a mixed bag. While significant funding is generated from consumer taxation, only 3.5 percent is earmarked and used for tobacco prevention and cessation programs. The objective of changing consumer behaviors is more complex, and stagnant smoking rates suggest its use to drive behavior has maxed out its utility. Regardless, revenues have declined due to reduced smoking rates, the emergence and widespread adoption of lower-taxed alternatives like ENDS, and illicit smuggling and trade.

The MSA requires tobacco companies to make perpetual annual payments totaling over $201 billion over the initial 25 years to 46 participating states to compensate for tobacco-related healthcare costs. Adjusted for inflation and sales volumes, these payments provide a steady revenue stream that benefits public health by funding treatment for smoking-related illnesses, prevention programs, and general healthcare services. By 2006, only 39 percent of MSA funds were allocated to general healthcare (including prevention and treatment), helping states avoid deeper cuts to health budgets during economic downturns.

The U.S. federal government derives financial benefits from the sales of tobacco and nicotine products as well, primarily through excise taxes and user fees. Federal excise taxes on traditional tobacco products support broad government operations by contributing to the general treasury, while user fees specifically fund regulatory oversight by the Food and Drug Administration (FDA). In fiscal year (FY) 2024, total federal excise tax revenue from tobacco products was approximately $9 billion—a significant drop from $14 billion in FY 2014. User fees, which do not apply to ENDS or most other nicotine-only products, total $712 million annually (plus any carryover from prior years) and are dedicated exclusively to the FDA’s Center for Tobacco Products (CTP).

The CTP uses these funds to support five key program areas:

• Scientific research and review of marketing applications (e.g., premarket tobacco product applications, modified risk claims).
• Compliance and enforcement (e.g., inspections, warning letters, seizures).
• Public education (e.g., youth campaigns like “The Real Cost”).
• Other communications (e.g., stakeholder outreach, guidance documents).
• Leadership, management oversight, and overhead costs associated with these activities.

In reality, the clear tension between revenue generation and public health policy affects manufacturers as well as state and federal policymakers. For each pack of cigarettes sold in the United States, state and federal governments receive approximately 45 percent of the retail price in the form of excise taxes, MSA distributions, and user fees. Additionally, the profit margin on reduced-risk products for manufacturers and retailers is minuscule compared to the profits related to the sale of combustible cigarettes.

Solving the smoking problem by reducing cigarette consumption and sales would also greatly decrease state revenues. The resulting conundrum requires policymakers to either introduce additional taxation or eliminate services—both of which are a tough sell. Furthermore, the potential for cost savings resulting from the reduction of smoking-related disease would be realized over decades rather than in real time, meaning funding gaps would have to be addressed. Simply increasing taxes on reduced-risk products is neither the easiest nor the best solution, since raising the costs on these products would reduce the likelihood that those who smoke would pay the higher premium when cigarettes remain more affordable.

Whether directly or indirectly, these pressures dramatically diminish the ability of a free-market solution to reduce tobacco-related death and disease in this country. Thus, the question remains: Does the importance of public health outweigh the need to acquire revenue? Policymakers’ response might provide the answer.